Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Anacapri
San Diego, California, United Statesanacapri.com.br ↗
- Ownership
- Private
- Employees
- ~136
- Development stage
- Other
01
Overview
AnaptysBio’s lead asset, rosnilimab, a PD‑1 depleter and agonist, has demonstrated “best-in-disease” efficacy in a robust global Phase 2b trial for moderate-to-severe rheumatoid arthritis with durable responses off drug and favorable safety compared to standard of care biologics or JAK inhibitors. Other clinical-stage programs include ANB032 (BTLA agonist) for atopic dermatitis. The company also has preclinical assets targeting CD122 and BDCA2. Multiple antibodies discovered by AnaptysBio have been licensed to partners such as GSK for immuno-oncology applications[6][5][3].
- Therapeutic areas
- DermatologyPulmonologyImmunologyGastroenterology
- Modalities
- Monoclonal antibodyAntibody (general)Cytokine antagonistSmall molecule
- Industry
- Biotech
02
Partnerships
GSK – multiple antibodies licensed including dostarlimab-gxly (“Jemperli”), cobolimab (“GSK4069889”), GSK4074386[5]Centessa Pharmaceuticals – exclusive license agreement for BDCA2 modulator ANB101[3]Vanda Pharmaceuticals – development/commercialization contract for imsidolimab[3]Sagard Healthcare Royalty Partners – royalty monetization agreement on JEMPERLI milestones [3]
Beyond the preview
Go deeper on Anacapri.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anacapri.